PT

Palvella Therapeutics, Inc.

PVLA·NASDAQ

$115.42

+10%
HealthcareBiotechnology

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.37B
EPS-3.7100
P/E Ratio-31.11
Earnings Date08/13/2026

pvla

Interest Expense

Last Annual Value

5.82M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

PT

Palvella Therapeutics, Inc. Competitors Analysis of Interest Expense

PVLA · NASDAQ
CompanyInterest Expense
CAGR 3Y
CAGR 5Y
CAGR 10Y
5.82M
N/AN/AN/A 
0.00
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
4.00K
-30.7%N/AN/A
1.51M
-0.8%29.6%10.1%
SVRA logo
Savara Inc.
NASDAQ:SVRA
0.00
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
2.60M
N/A89.6%N/A
97.00K
-40.4%-49.2%N/A
-33.00K
N/AN/AN/A
PT

Palvella Therapeutics, Inc. Fair Value Envelope

PVLA · NASDAQ

Our analysis suggests that PVLA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $115.42, this represents a potential HIDDEN relative to our calculated worth for Palvella Therapeutics, Inc..

Intrinsic Value
Current Price: $115.42